Mezavant

Mesalazine, the active ingredient in Mezavant, is a 5-aminosalicylic acid (5-ASA) presented as an oral formulation for oral use. It treats ulcerative colitis in adult patients by reducing intestinal inflammation and helping maintain remission.

GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for global healthcare providers.

Mezavant (mesalazine) is used to manage inflammatory conditions of the colon, primarily ulcerative colitis.

- Ulcerative colitis (induction): reduces mucosal inflammation to induce remission in active disease. - Ulcerative colitis (maintenance): helps sustain remission and prevent relapse. - Mild to moderate ulcerative colitis: provides topical anti‑inflammatory effect throughout the colon.

Adverse reactions may occur with mesalazine therapy. Most are mild and reversible, but serious events are reported in a minority of patients.

Common Side Effects: - Nausea - Abdominal pain - Headache - Flatulence

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Myocarditis - Pancreatitis

Before initiating Mezavant, clinicians should evaluate patient-specific risk factors and monitor for potential complications. - Renal function: assess baseline and monitor periodically for renal impairment. - Hepatic function: check liver enzymes before treatment and during therapy. - Disease activity: ensure active ulcerative colitis is appropriately diagnosed. - Hypersensitivity: avoid in patients with known allergy to mesalazine or related compounds. - Sulfonamide sensitivity: use caution in patients with sulfonamide intolerance. - Store at ambient temperature: keep in the original container, protect from moisture.

Mesalazine can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Azathioprine: may increase risk of bone marrow suppression. - Warfarin: can enhance anticoagulant effect, raising bleeding risk. - Methotrexate: potential for additive toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy. - NSAIDs: increase gastrointestinal irritation. - Lithium: possible alteration of serum lithium levels.